Details

Autor(en) / Beteiligte

• Stangou, Maria
• Marinaki, Smaragdi
• Papachristou, Evangelos
• Kolovou, Kyriaki
• Sambani, Erasmia
• Zerbala, Synodi
• Papadea, Panagiota
• Balafa, Olga
• Rapsomanikis, Karolos-Pavlos
• Andrikos, Aimilios
• Manolakaki, Panagiota
• Papadopoulou, Dorothea
• Mitsopoulos, Efstathios
• Liakou, Helen
• Andronikidi, Paraskevi-Evi
• Choulitoudi, Vasiliki
• Moustakas, George
• Galitsiou, Dimitra
• Dafnis, Eugene
• Stylianou, Kostas
• Stefanidis, Ioannis
• Golfinopoulos, Spyridon
• Panagoutsos, Stylianos
• Tsilivigkou, Maria
• Papadogianakis, Apostolos
• Tzanakis, Ioannis
• Sioulis, Athanasios
• Vlachakos, Dimitrios
• Grapsa, Eirini
• Spaia, Sophia
• Kaperonis, Nikolaos
• Paliouras, Christos
• Dioudis, Christos
• Papoulidou, Fani
• Apostolou, Theofanis
• Iatrou, Christos
• Boletis, Ioannis
• Goumenos, Dimitrios
• Papagianni, Aikaperini
• Jha, Vivekanand

Titel

Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy

Ist Teil von

• PloS one, 2019-08, Vol.14 (8), p.e0217116

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Management of the Primary Membranous Nephropathy (PMN) usually involves administration of immunosuppressives. Cyclophosphamide (Cyclo) and Calcineurin Inhibitors (CNIs) are both widely used but only limited data exist to compare their efficacy in long term follow-up. The aim of the present study was to estimate and compare long term effects of Cyclo and CNIs in patients with PMN. Clinical data, histologic findings and long term outcome were retrospectively studied. The response to treatment and rate of relapse was compared between patients treated with CNIs or Cyclo based immunosuppressive regimens. Twenty three centers participated in the study, with 752 PMN patients (Mean age 53.4(14-87) yrs, M/F 467/285), followed for 10.1±5.7 years. All patients were initially treated with Renin Angiotensin Aldosterone System inhibitors (RAASi) for at least 6 months. Based on their response and tolerance to initial treatment, patients were divided into 3 groups, group I with spontaneous remission, who had no further treatment, group II, continued on RAASi only, and group III on RAASi+immunosuppression. Immunosuppressive regimes were mainly based on CNIs or Cyclo. Frequent relapses and failure to treatment were more common between patients who had started on CNIs (n = 381) compared to those initially treated with Cyclo (n = 110), relapse rate: 25.2% vs. 6.4%, p<0.0001, and no response rate: 22.5% vs. 13.6%, p = 0.04, respectively. Long term follow up showed that administration of Cyclo in PMN is followed by better preservation of renal function, increased response rate and less frequent relapses, compared to CNIs.